Evaluation of Early Postoperative Period Results of Patients With Type 2 Diabetes Taking Oral Anti-Diabetics Or Insulin Medications, With Microalbuminuria and Normal Creatinine Levels After Coronary Artery Bypass
DOI:
https://doi.org/10.1532/hsf.4621Keywords:
Type 2 diabetes mellitus, insulin, oral antidiabetic, coronary artery bypassAbstract
Background: Acute kidney injury (AKI) is one of the most important complications after cardiac surgery and is one of the main causes of morbidity and mortality. Diabetes mellitus also is one of the main risk factors for renal dysfunction in coronary artery bypass graft (CABG). In this study, we aimed to compare the early postoperative period results of type 2 diabetes patients taking oral antidiabetics (OAD) or insulin medications, with microalbuminuria and normal creatinine levels after CABG.
Methods: Eighty patients with type 2 diabetes and taking OAD or receiving insulin medication all with normal creatinine levels with microalbuminuria were included in this study. Preoperative creatinine values of the patients, albumin levels in spot urine, creatinine levels on the postoperative 3rd day, duration of ventilation, amount of drainage, length of stay in the intensive care unit, length of stay in the hospital, mediastinitis, and mortality rates were recorded.
Results: A statistically significant increase in creatinine was found in both taking OAD type 2 diabetes and insulin medication with microalbuminuria. When the two groups were compared with each other, the increase in creatinine levels of the patients using insulin was higher than the patients taking OAD. It also was statistically significant.
Conclusion: According to the result of our study, it can be suggested that postoperative creatinine elevation is observed in patients with type 2 diabetes mellitus with microalbuminuria and with normal creatinine levels, either having insulin medication or not. The elevation is higher in patients having insulin medication, while other results are similar, except for impaired renal function.
References
Almassi GH, Sommers T, Moritz TE, et al. 1999. Stroke in cardiac surgical patients: determinants and outcome. Ann Thorac Surg. 68(2):391-7.
Amann K, Wanner C, Ritz E. 2006. Cross-talk between the kidney and the cardiovascular system. J Am Soc Nephrol. 17:2112-19.
Asimakopoulos G, Smith PL, Ratnatunga CP, et al. 1999. Lung injury and acute respiratory distress syndrome after cardiopulmonary bypass. Ann Thorac Surg. 68(3):1107-15.
Carson J, Scholz PM, Chen A, et al. 2002. Diabetes mellitus increases short-term mortality and morbidity in patients undergoing coronary artery bypass graft surgery. J Am Coll Cardiol. 40:418-23.
Cohen Y, Raz I, Merin G, et al. 1998. Comparison of factors associated with 30 -day mortality after coronary artery bypass grafting in patients with versus without diabetes mellitus. Am J Cardiol. 81:7-11.
Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, et al. 1989. Albuminuria reflects widespread vascular damage. The Steno hypothesis. Diabetologia. 32:219-26.
Eagle KA, Guyton RA, Davidoff R, et al. 1999. ACC/AHA Guidelines for Coronary Artery Bypass Graft Surgery: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1991 Guidelines for Coronary Artery Bypass Graft Surgery). American College of Cardiology/American Heart Association. J Am Coll Cardiol. 34(4):1262-347.
Francel TJ, Kouchoukos NT. 2001. A rational approach to wound difficulties after sternotomy: the problem. Ann Thorac Surg. 72:1411-8.
Gerstein HC, Mann JF, Yi Q, et al. 2001. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA. 286:421-6.
Gulack BC, Kirkwood KA, Shi W, et al. 2018. Secondary surgical-site infection after coronary artery bypass grafting: A multi-institutional prospective cohort study. J Thorac Cardiovasc Surg. 155(4):1555-62.
Gültekin Y, Bolat A. 2020. Bir üniversite hastanesi kliniğinde yapılan ilk 200 açık kalp ameliyatı sonuçları: Kırıkkale Üniversitesi, Tıp Fakültesi, Kalp-Damar Cerrahisi, KÜ Tıp Fak Derg. 22(3):348-56.
Gultekin Y, Bolat A, Hatice K, et al. 2021. Does Aspartate Aminotransferase to Alanine Aminotransferase Ratio Predict Acute Kidney Injury After Cardiac Surgery? Heart Surg Forum. 24(3):506-11.
Jarraya F, Lakhdar R, Kammoun K, et al. 2013. Microalbuminuria A Useful Marker of Cardiovascular Disease. Iranıan J Kidney Dis. 7(3):178-86.
Jensen T, Borch-Johnsen K, Kofoed-Enevoldsen A, et al. 1987. Coronary heart disease in young type I (insulin-dependent) diabetic patients with and without diabetic nephropathy: incidence and risk factors. Diabetologia. 30:144-8.
Kunt AT, Akgün S, Atalan S, et al. 2009. Furosemide infusion prevents the requirement of renal replacement therapy after cardiac surgery. Anadolu Kardiyol Derg. 9:499-504.
Levy JH, Tanaka KA. 2003. Inflammatory response to cardiopulmonary bypass. Ann Thorac Surg. 75(2): 715-20.
Mangano CM, Diamondstone LS, Ramsay JG, et al. 1998. Renal dysfunction after myocardial revascularization: risk factors, adverse outcomes, and hospital resource utilization. The Multicenter Study of Perioperative Ischemia Research Group. Ann Intern Med. 128(3):194-203.
Mazzarella V, Gallucci MT, Tozzo C, et al. 1992. Renal function in patients undergoing cardiopulmonary bypass operations. J Thorac Cardiovasc Surg. 104(6):1625–7.
Mirmohammad-Sadeghi M, Naghiloo A, Najarzadegan MR. 2013. Evaluating the relative frequency and predicting factors of acute renal failure following coronary artery bypass grafting. ARYA Atheroscler. 9:287–92.
Mishra J, Dent C, Tarabishi R, et al. 2005 Neutrophil gelatinase-associated lipocalin (NGAL) as biomarker for acute renal injury following cardiac surgery. Lancet. 365:1231-8.
Mogensen CE. 1984. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med. 6:356-60.
Patrick AW, Leslie PJ, Clarke BF, et al. 1990. Natural history and associations of microalbuminuria in type 2 diabetes during the first year after diagnosis, Diabet Med. 7: 902-8.
Perkins BA, Ficociello LH, Ostrander BE, et al. 2007. Microalbuminuria and the risk for early progressive renal function decline in type 1 diabetes. J Am Soc Nephrol. 18:1353-61.
Remuzzi G, Bertani T. 1990. Is glomerulosclerosis a consequence of altered glomerular permeability to macromolecules? Kidney Int. 38:384-94.
Shafranskaya KS, Kashtalap VV, Kutikhin AG, et al. 2015. Microalbuminuria and prediction of cardiovascular complications in patients with coronary artery disease and type 2 diabetes mellitus after CABG surgery. Heart Lung Circ. 24(10):951-9.
Thourani VH, Weintraub WS, Stein B, et al. 1999. Influence of diabetes mellitus on early and late outcome after coronary artery bypass grafting. Ann Thorac Surg. 67:1045-52.
Turner R, Millins H, Neil H, et al. 1998. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS: 23) the United Kingdom Prospective Diabetes Study Group. BMJ. 316: 823-28.
Vazquez-Benitez G, Desai JR, Xu S, et al. 2015. Preventable major cardiovascular events associated with uncontrolled glucose, blood pressure, and lipids and active smoking in adults with diabetes with and without cardiovascular disease: a contemporary analysis. Diabetes Care. 38(5): 905-12.
Viberti GC, Hill RD, Jarrett RJ, et al. 1982. Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus. Lancet. 1(8287):1430-2.
Yavuz S, Ayabakan N, Goncu MT, et al. 2002. Effect of combined dopamine and diltiazem on renal function after cardiac surgery. Med Sci Monit. 8(5):145-50.
Yudkin JS, Forrest RD, Jackson CA, 1988. Microalbuminuria as predictor of vascular disease in non-diabetic subjects. Islington Diabetes Survey. Lancet 2(8610):530–3.
Zarich SW, Arbuckle BE, Cohen LR, et al. 1988. Diastolic abnormalities in young asymptomatic diabetic patients assessed by pulsed Doppler echocardiography. J Am Coll Cardiol. 12:114-20.
Published
How to Cite
Issue
Section
Author Disclosure & Copyright Transfer Agreement
In order to publish the original work of another person(s), The Heart Surgery Forum® must receive an acknowledgment of the Author Agreement and Copyright Transfer Statement transferring to Forum Multimedia Publishing, L.L.C., a subsidiary of Carden Jennings Publishing Co., Ltd. the exclusive rights to print and distribute the author(s) work in all media forms. Failure to check Copyright Transfer agreement box below will delay publication of the manuscript.
A current form follows:
The author(s) hereby transfer(s), assign(s), or otherwise convey(s) all copyright ownership of the manuscript submitted to Forum Multimedia Publishing, LLC (Publisher). The copyright transfer covers the exclusive rights to reproduce and distribute the article and the material contained therein throughout the world in all languages and in all media of expression now known or later developed, including but not limited to reprints, photographic reproduction, microfilm, electronic data processing (including programming, storage, and transmission to other electronic data record(s), or any other reproductions of similar nature), and translations.
However, Publisher grants back to the author(s) the following:
- The right to make and distribute copies of all or part of this work for use of the author(s) in teaching;
- The right to use, after publication in The Heart Surgery Forum, all or part of the material from this work in a book by the author(s), or in a collection of work by the author(s);
- The royalty-free right to make copies of this work for internal distribution within the institution/company that employs the author(s) subject to the provisions below for a work-made-for-hire;
- The right to use figures and tables from this work, and up to 250 words of text, for any purpose;
- The right to make oral presentations of material from this work.
Publisher reserves the right to grant or refuse permission to third parties to republish all or part of the article or translations thereof. To republish, such third parties must obtain written permission from the Publisher. (This is in accordance with the Copyright Statute, United States Code, Title 17. Exception: If all authors were bona fide officers or employees of the U.S. Government at the time the paper was prepared, the work is a “work of the US Government” (prepared by an officer or employee of the US Government as part of official duties), and therefore is not subject to US copyright; such exception should be indicated on signature lines. If this work was prepared under US Government contract or grant, the US Government may reproduce, royalty-free, all or portions of this work and may authorize others to do so, for official US Government purposes only, if the US Government contract or grant so requires.
I have participated in the conception and design of this work and in the writing of the manuscript and take public responsibility for it. Neither this manuscript nor one with substantially similar content under my authorship has been published, has been submitted for publication elsewhere, or will be submitted for publication elsewhere while under consideration by The Heart Surgery Forum, except as described in an attachment. I have reviewed this manuscript (original version) and approve its submission. If I am listed above as corresponding author, I will provide all authors with information regarding this manuscript and will obtain their approval before submitting any revision. I attest to the validity, accuracy, and legitimacy of the content of the manuscript and understand that Publisher assumes no responsibility for the validity, accuracy, and legitimacy of its content. I warrant that this manuscript is original with me and that I have full power to make this Agreement. I warrant that it contains no matter that is libelous or otherwise unlawful or that invades individual privacy or infringes any copyright or other proprietary right. I agree to indemnify and hold Publisher harmless of and from any claim made against Publisher that relates to or arises out of the publication of the manuscript and agree that this indemnification shall include payment of all costs and expenses relating to the defense of any such claim, including all reasonable attorney’s fees.
I warrant that I have no financial interest in the drugs, devices, or procedures described in the manuscript (except as disclosed in the attached statement).
I state that the institutional Human Subjects Committee and/or the Ethics Committee approved the clinical protocol reported in this manuscript for the use of experimental techniques, drugs, or devices in human subjects and appropriate informed consent documents were utilized.
Furthermore, I state that any and all animals used for experimental purposes received humane care in USDA registered facilities in compliance with the “Principles of Laboratory Animal Care” formulated by the National Society for Medical Research and the “Guide for the Care and Use of Laboratory Animals” prepared by the Institute of Laboratory Animal Resources and published by the National Institutes of Health (NIH Publication No. 85-23, revised 1985).